Clinical characteristics and economic costs of patients with painful neuropathic disorders

被引:269
作者
Berger, A
Dukes, EM
Oster, G
机构
[1] Policy Anal Inc, Brookline, MA 02445 USA
[2] Pfizer Inc, Outcomes Res, New York, NY USA
关键词
analgesics; neuralgia; costs; cost analysis;
D O I
10.1016/j.jpain.2003.12.004
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Using a large US health insurance claims database, we identified all persons aged 18 years or older with 2 or more medical encounters in calendar year 2000 for painful neuropathic disorders (PNDs). We also identified an age- and gender-matched group of patients without PNDs (matched control subjects). We then compared the clinical characteristics and economic costs of PND patients with those of matched control subjects. There were a total of 55,686 patients with PNDs in the study database. The most frequently noted PNDs were back and neck pain with neuropathic involvement (62.3% of PND patients), causalgia (12.1%), and diabetic neuropathy (10.8%). In comparison with matched control subjects, PND patients were more likely to have other pain-related conditions, including fibromyalgia (6.0% vs 0.6% for control subjects), osteoarthritis (13.6% vs 3.6%), and other chronic comorbidities, such as coronary heart disease (13.6% vs 6.5%) and depression (6.4% vs 2.3%). Total calendar year 2000 health care charges were 3-fold higher for PND patients than matched control subjects ($17,355 vs $5,715, respectively). Our results suggest that patients with PNDs are generally in poorer health and have higher health care costs than their peers without these conditions. Perspective: Use of nonsteroidal anti-inflammatory agents and opioids was widespread in patients with PNDs, while relatively few received antiepileptic drugs and tricyclic antidepressants, both of which are often more effective against neuropathic pain. Our study raises questions about the optimality of PND treatment in clinical practice. (C) 2004 by the American Pain Society.
引用
收藏
页码:143 / 149
页数:7
相关论文
共 43 条
[1]  
[Anonymous], 1994, CLASSIFICATION CHRON
[2]   LACK OF ANALGESIC EFFECT OF OPIOIDS ON NEUROPATHIC AND IDIOPATHIC FORMS OF PAIN [J].
ARNER, S ;
MEYERSON, BA .
PAIN, 1988, 33 (01) :11-23
[3]   Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus - A randomized controlled trial [J].
Backonja, M ;
Beydoun, A ;
Edwards, KR ;
Schwartz, SL ;
Fonseca, V ;
Hes, M ;
LaMoreaux, L ;
Garofalo, E .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (21) :1831-1836
[4]   Anticonvulsants (antineuropathics) for neuropathic pain syndromes [J].
Backonja, MM .
CLINICAL JOURNAL OF PAIN, 2000, 16 (02) :S67-S72
[5]   Use of anticonvulsants for treatment of neuropathic pain [J].
Backonja, MM .
NEUROLOGY, 2002, 59 (05) :S14-S17
[6]   Treatment options in postherpetic neuralgia [J].
Bonezzi, C ;
Demartini, L .
ACTA NEUROLOGICA SCANDINAVICA, 1999, 100 :25-35
[7]   CLINICAL TRIAL OF CARBAZEPINE (TEGRETOL) IN TRIGEMINAL NEURALGIA [J].
CAMPBELL, FG ;
GRAHAM, JG ;
ZILKHA, KJ .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1966, 29 (03) :265-&
[8]   Rationale and evidence for the use of oxcarbazepine in neuropathic pain [J].
Carrazana, E ;
Mikoshiba, I .
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2003, 25 (05) :S31-S35
[9]   EFFICACY AND SAFETY OF NONSTEROIDAL ANTIINFLAMMATORY DRUGS IN THE THERAPY OF DIABETIC NEUROPATHY [J].
COHEN, KL ;
HARRIS, S .
ARCHIVES OF INTERNAL MEDICINE, 1987, 147 (08) :1442-1444
[10]   An overview of neuropathic pain: Syndromes, symptoms, signs, and several mechanisms [J].
Dworkin, RH .
CLINICAL JOURNAL OF PAIN, 2002, 18 (06) :343-349